Cargando…
TIPS improves outcomes in patients with HCC and symptomatic portal hypertension: a multi-institution experience
BACKGROUND: Hepatocellular carcinoma (HCC) with symptomatic portal hypertension (SPH) has poor prognosis. A transjugular intrahepatic portosystemic shunt (TIPS) relieves SPH, but its application in HCC remains unclear. We evaluated TIPS efficacy in patients with HCC and SPH. METHODS: Pre- and post-T...
Autores principales: | Yan, Huzheng, Qiu, Zhenkang, Xiang, Zhanwang, Feng, Kai, Huang, Mingsheng, Gao, Fei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858571/ https://www.ncbi.nlm.nih.gov/pubmed/35183265 http://dx.doi.org/10.1186/s40644-022-00451-9 |
Ejemplares similares
-
TIPS plus sequential systemic therapy of advanced HCC patients with tumour thrombus-related symptomatic portal hypertension
por: Qiu, Zhenkang, et al.
Publicado: (2022) -
Feasibility and clinical value of TIPS combined with subsequent antitumor treatment in HCC patients with refractory ascites
por: Yan, Huzheng, et al.
Publicado: (2020) -
Whole-course management of interventional treatment in liver cancer patients with portal hypertension
por: Qiu, Zhenkang, et al.
Publicado: (2019) -
Clinical efficacy and prognostic factors of CT-guided (125)I brachytherapy for the palliative treatment of retroperitoneal metastatic lymph nodes
por: Yan, Huzheng, et al.
Publicado: (2020) -
TACE Combined with Lenvatinib and Camrelizumab for Unresectable Multiple Nodular and Large Hepatocellular Carcinoma (>5 cm)
por: Xiang, Zhanwang, et al.
Publicado: (2023)